Angela Chau, Ming-Lun Yeh, Pei-Chien Tsai, Daniel Q Huang, Sung Eun Kim, Huy Trinh, Eileen L Yoon, Hyunwoo Oh, Jae Yoon Jeong, Sang Bong Ahn, Jihyun An, Cheng-Hao Tseng, Yao-Chun Hsu, Soung Won Jeong, Yong Kyun Cho, Jae-Jun Shim, Hyoung Su Kim, Takanori Ito, Sebastián Marciano, Keigo Kawashima, Takanori Suzuki, Tsunamasa Watanabe, Akito Nozaki, Toru Ishikawa, Kaori Inoue, Yuichiro Eguchi, Haruki Uojima, Hiroshi Abe, Hirokazu Takahashi, Makoto Chuma, Masatoshi Ishigami, Joseph K Hoang, Maeda Mayumi, Chung-Feng Huang, Adrian Gadano, Chia-Yen Dai, Jee-Fu Huang, Yasuhito Tanaka, Wan-Long Chuang, Seng Gee Lim, Ramsey Cheung, Ming-Lung Yu, Dae-Won Jun, Mindie H Nguyen
BACKGROUND: It is unclear if there may be sex differences in response to nucleos(t)ide analogs (NA) including viral suppression [VR], biochemical response [BR], complete response [CR], and HCC incidence among hepatitis B patients. We compared NA treatment outcomes by sex. APPROACH: A retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female; 2138 male) from the REAL-B consortium who initiated therapy with either entecavir or tenofovir from 22 sites (Argentina, Korea, Japan, Taiwan, USA)...
September 19, 2023: Clinical Gastroenterology and Hepatology